Candel Therapeutics启动针对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者的全球关键Aurora三期试验，评估Aglatimagene Besadenovec (CAN-2409)疗效

美股速递06-30

Candel Therapeutics 已启动一项名为Aurora的全球关键性三期临床试验，旨在评估Aglatimagene Besadenovec（CAN-2409）在那些对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者中的疗效。该试验标志着公司候选药物开发进程中的一个重要里程碑。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1123511344?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-30 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123511344","market":"us","top_or_hot":-1,"title":"Candel Therapeutics启动针对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者的全球关键Aurora三期试验，评估Aglatimagene Besadenovec (CAN-2409)疗效","media":"美股速递","content":"<p>Candel Therapeutics 已启动一项名为Aurora的全球关键性三期临床试验，旨在评估Aglatimagene Besadenovec（CAN-2409）在那些对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者中的疗效。该试验标志着公司候选药物开发进程中的一个重要里程碑。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics启动针对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者的全球关键Aurora三期试验，评估Aglatimagene Besadenovec (CAN-2409)疗效</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics启动针对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者的全球关键Aurora三期试验，评估Aglatimagene Besadenovec (CAN-2409)疗效\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-30 20:05 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Candel Therapeutics 已启动一项名为Aurora的全球关键性三期临床试验，旨在评估Aglatimagene Besadenovec（CAN-2409）在那些对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者中的疗效。该试验标志着公司候选药物开发进程中的一个重要里程碑。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CADL","symbol_name":"Candel Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1123511344","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123511344","pubTimestamp":1782821131,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Candel Therapeutics 已启动一项名为Aurora的全球关键性三期临床试验，旨在评估Aglatimagene Besadenovec（CAN-2409）在那些对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者中的疗效。该试验标志着公司候选药物开发进程中的一个重要里程碑。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CADL":"Candel Therapeutics, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"Candel Therapeutics initiates global pivotal Aurora Phase III trial to evaluate Aglatimagene Besadenovec (CAN-2409) efficacy in patients with advanced non-small cell lung cancer with poor response to immune checkpoint inhibitors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":1},"content_text":"Candel Therapeutics 已启动一项名为Aurora的全球关键性三期临床试验，旨在评估Aglatimagene Besadenovec（CAN-2409）在那些对免疫检查点抑制剂反应不佳的晚期非小细胞肺癌患者中的疗效。该试验标志着公司候选药物开发进程中的一个重要里程碑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123511344","isCrawlerRequest":true}